Active Pipeline:
HG-CT-1 - Hemogenyx CAR-T for R/R AML + expanding to pediatrics in H1 2025 targeting FLT3 which has recently been proven as an extremely promising and effective target. Significant interest in CAR-T treatments with each treatment 200k+, licensing deals in the range of 500m->1bn+ (including milestone payments)
CDX - Building on same FLT3 target expands use of bi-specific antibody to a whole range of blood borne cancers and diseases including auto-immune. Off the shelf + cheap to manufacture, success of HG-CT-1 will be of significant importance here.
CBR - Potential to cure any virus + range of cancers and other conditions, recent breakthroughs include nasal delivery and ability to pass brain blood barrier. Scope for interest by US Defense in the fight against Bio terrorism and Disease X.
Target market for each of the above is in the billions, current mCap = 14m.
Debt = Zero.
Reason for current low mCap? Company has relied on a small pool of UK investors to fundraise for the past several years, each increment has relied on same pool whom have taken to short selling and dumping to increase dilution and discounts they took and made it hard for company to fund raise. Company have broken away from this investor pool and engaged US based investment brokers, expect to see US based investment in the near future + potential for near term grants/JV and licensing opportunities.
How well do narratives help inform your perspective?
Disclaimer
The user FactsNotFiction holds no position in LSE:HEMO. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.